Nalmefene: Blockade of intravenous morphine challenge effects in opioid abusing humans

Drug and Alcohol Dependence

Volumn 60, Issue 1, 2000, Pages 29-37

  Jones, Hendrée E ^a,b   Johnson, Rolley E ^a   Fudala, Paul J ^c   Henningfield, Jack E ^a,d   Heishman, Stephen J ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PINNEY ASSOCIATES   (United States)

^e Intramural Research Program   (United States)

Author keywords

Blockade; Morphine; Nalmefene; Pharmacology; Subjective effects

Indexed keywords

MORPHINE; NALMEFENE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG ANTAGONISM; HUMAN; HUMAN EXPERIMENT; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0342749342     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(00)80005-8     Document Type: Article

References (35)

1. Aceto M.D., Harris L.S., May E.L. Dependence studies of new compounds in the rhesus monkey, rat and mouse. Harris L. Proceedings, Committee of Problems of Drug Dependence, National Drug Abuse Research Monograph. 1986;399-452 US Gov Printing Office, Washington D.C.
2. Barsan W.G., Seger D., Danzl D.F., Ling L.J., Bartlett R., Buncher R., Bryan C. Duration of antagonistic effects of nalmefene and naloxone in opioid-induced sedation for emergency department procedures. Am. J. Emerg. Med. 7:1989;155-161.
3. Cohen J. 2nd edition Statistical Power Analysis for the Behavioral Sciences. 1988;Lawrence Erlbaum Associates, Hillsdale, NJ.
4. Dixon R., Gentile J., Hsu H.-B., Hsiao J., Howes J., Garg D., Weidler D. Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist. J. Clin. Pharmacol. 27:1987;233-239.
5. Dyson D.H., Doherty T., Anderson G.I., McDonell W.N. Reversal of oxymorphone sedation by naloxone, nalmefene and butorphanol. Vet. Surg. 19:1990;398-403.
6. Emmerson P.J., Liu M.R., Woods J.H., Medzihradsky F. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271:1994;1630-1637.
7. Fishman J., Roffwarg H., Hellman L. Disposition of naloxone in normal and narcotic dependent man. J. Pharmacol. Exp. Ther. 187:1973;575-580.
8. France C.P., Gerak L.R. Behavioral effects of 6-methylene naltrexone (nalmefene) in rhesus monkeys. J. Pharmacol. Exp. Ther. 270:1994;992-999.
9. France C.P., Woods J.H. Morphine, saline and naltrexone discrimination in morphine-treated pigeons. J. Pharmacol. Exp. Ther. 242:1987;195-202.
10. Frye R.F., Matzke G.R., Schade R., Dixon R., Rabinovitz M. Effects of liver disease on the disposition of the opioid antagonist nalmefene. Clin. Pharmacol. Ther. 61:1997;15-23.
11. Fudala P.J., Heishman S.J., Henningfield J.E., Johnson R.E. Human pharmacology and abuse potential of nalmefene. Clin. Pharmacol. Ther. 49:1991;300-306.
12. Gal T.J., DiFazio C.A. Prolonged antagonism of opioid action with intravenous nalmefene in man. Anesthesiology. 64:1986;175-180.
13. Gal T.J., DiFazio C.A., Dixon R. Prolonged blockade of opioid effect with oral nalmefene. Clin. Pharmacol. Ther. 40:1986;537-542.
14. Ginzburg H.M., Ginzberg M.D., Glass W.J. The role of the national institute on drug abuse in the development of naltrexone. J. Clin. Psychiatry. 45:1984;39-41.
15. Glass P.S., Jhaveri R.M., Smith L.R. Comparison of potency and duration of action of nalmefene and naloxone. Anesth. Analg. 78:1994;536-541.
16. Gonzalez J.P., Brogden R.N. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 35:1988;192-213.
17. Haertzen C.A. An Overview of Addiction Research Center Inventory (ARCI): An Appendix and Manual of Scales. 1974;Department of Health, Education, and Welfare, Washington D.C. DHEW publication no. (ADM) 79.
18. Hahn E.F., Fischman J. Narcotic antagonists. 4. carbon-6 derivatives of N-substituted noroxymorphones as narcotic antagonists. J. Med. Chem. 18:1975;259-262.
19. Jasinski D.R. Assessment of abuse potentiality of morphine-like drugs (methods used in man). Martin W.R. Handbook of Experimental Pharmacology: Drug Addiction. I. Morphine, Sedative-Hypnotic and Alcohol Dependence. 1977;197-258 Springer-Verlag, Heidelberg.
20. Jasinski D.R., Martin W.R., Sapira J.D. Antagonism of the subjective behavioral, pupillary, and respiratory depressant effects of cyclazocine by naloxone. Clin. Pharmacol. Ther. 9:1968;215-222.
21. Kleber H.D. Naltrexone. J. Subst. Abuse Treat. 2:1985;117-122.
22. Konieczko K.M., Jones J.G., Barrowcliffe M.P., Jordan C., Altman D.G. Antagonism of morphine-induced respiratory depression with nalmefene. Br. J. Pharmacol. 61:1988;318-323.
23. Marquardt W.G., Martin W.R., Jasinski D.R. The use of the Polaroid close-up camera in pupilography. Int. J. Addiction. 2:1967;301-304.
24. Mason B.J., Salvato F.R., Williams L.D., Rivto E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry. 56:1999;719-724.
25. Michel M.E., Bolger G., Weissman B.-A. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Find. Exp. Clin. Pharmacol. 7:1985;175-177.
26. Nagarajan R., Jeyashree S., Shanmugam M., Subramanian V.B., Tuttle R.R., Caldwell R.W. Reversal of effects of morphine by nalmefene. J. Clin. Res. Drug Dev. 7:1992;25-29.
27. Effective medical treatment of opiate addiction. J. Am. Med. Assoc. 280:1998;1936-1943.
28. Ngai S.H., Berkowitz B.A., Yang J.C., Hempstead J., Spector S. Pharmacokinetics of naloxone in rats and man: basis for its potency and short duration of action. Anesthesiology. 44:1976;398-401.
29. O'Connor P.G., Kosten T.R. Management of opioid intoxication and withdrawal. Graham A.W., Schultz T.K. second edition Principles of Addiction Medicine. 1998;457-464 American Society of Addiction Medicine, Chevy Chase.
30. Prendergast M.L., Grella C., Perry S.M., Anglin M.D. Levo-Alpha-Acetylmethadol (LAAM): clinical, research and policy issues of a new pharmacotherapy for opioid addiction. J. Psychoactive Drugs. 27:1995;239-247.
31. Stine S.M., Meandzija B., Kosten T.R. Pharmacologic therapies for opioid addiction. Graham A.W., Schultz T.K. second edition Principles of Addiction Medicine. 1998;545-555 American Society of Addiction Medicine, Chevy Chase.
32. Van Vugt D.A., Webb M.Y., Reid R.L. Comparison of the duration of action of nalmefene on the hypothalamic-pituitary axis of the rhesus monkey. Neuroendocrinology. 49:1989;275-280.
33. Vereby K., Volavka J., Mule S.J., Resnick R.B. Naltrexone: disposition, metabolism, and effects after acute and chronic dosing. Clin. Pharmacol. Ther. 20:1976;315-328.
34. Wilhelm J.A., Veng-Pedersen P., Zakszewski T.B., Osifchin E., Waters S.J. Duration of opioid antagonism by nalmefene and naloxone in the dog. Int. J. Clin. Pharmacol. Ther. 33:1995;540-545.
35. Zaks A., Jones T., Fink M., Freedman B.M. Naloxone treatment of opiate dependence. J. Am. Med. Assoc. 215:1971;2108-2110.